Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IW-3300 for Bladder Pain in IC/BPS
NCT05740007Phase 2Terminated
- Sponsor
- Ironwood Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IW-3300 in Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS), sponsored by Ironwood Pharmaceuticals. Primary endpoint: Change from baseline in weekly average of daily bladder pain at its worst at Week 12. Started Mar 2023; status: terminated.
02
Drugs
IW-3300
03
Conditions
Interstitial Cystitis-Bladder Pain Syndrome (IC/BPS)
Beyond the preview
Go deeper on NCT05740007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05740007.